Epitome Therapeutics, a biotechnology startup developing a novel approach to precise epigenome editing for the targeted regulation of

Epitome Therapeutics 是一家生物技术初创公司，正在开发一种用于靶向调控的新型表观基因组精准编辑方法

gene expression

基因表达

, announces its official launch with total funding of 4 million euros. This funding consists of an oversubscribed pre-seed

，宣布正式启动，总融资额为400万欧元。该轮融资由超额认购的预种子轮组成

financing

融资

round of 2 million euros, as well as an additional 2 million euros in grants. The pre-seed round was co-led by XISTA Science Ventures and Caesar Ventures; Navec Venture Holding GmbH also participated. Additional funds were secured through competitive grant programs, including support from Austria Wirtschaftsservice (AWS) and the Austrian Research Promotion Agency (FFG)..

200万欧元的融资轮次，以及额外的200万欧元补助资金。该预种子轮融资由XISTA Science Ventures和Caesar Ventures联合领投，Navec Venture Holding GmbH也参与其中。此外，还通过竞争性补助计划获得了额外资金，包括来自奥地利经济服务局（AWS）和奥地利研究促进署（FFG）的支持。

The funds from this financing will be used to advance Epitome Therapeutics’ development programs toward the nomination of a first drug candidate, expand the technological scope of the CADENCE platform, and grow the company’s scientific and operational teams.

本次融资所得资金将用于推进 Epitome Therapeutics 的研发项目，以提名首个候选药物；扩大 CADENCE 平台的技术范围；并壮大公司的科学与运营团队。

“We founded Epitome Therapeutics with the support of a strong group of investors and partners,” said Dr. Guido Gualdoni, co-founder and CEO of Epitome Therapeutics. “The successful completion of an oversubscribed financing round is a strong testament to the quality of our team and the potential of the CADENCE platform.

“我们在众多实力雄厚的投资者和合作伙伴的支持下创立了Epitome Therapeutics，”Epitome Therapeutics联合创始人兼首席执行官Guido Gualdoni博士表示。“超额认购的融资轮次圆满完成，充分证明了我们团队的实力以及CADENCE平台的巨大潜力。”

The new funds will enable us to further expand the company based on CADENCE technology and translate our scientific findings into initial development programs. Our immediate focus is now on expanding the platform, strengthening our team, and advancing the selection of our first drug candidate.”.

新资金将使我们能够基于CADENCE技术进一步扩展公司，并将我们的科学发现转化为初步开发项目。我们当前的重点是扩大平台、加强团队建设，并推进首个候选药物的筛选工作。

Extreme Mutation Hotspot in Bacteria Discovered: Study Links High Mutation Rates to Transcriptional Activation

发现细菌中的极端突变热点：研究将高突变率与转录激活联系起来

Groundbreaking research identifies a 5000-fold increase in mutation rates in the promoter of a bacterial gene

突破性研究发现，细菌基因启动子区域的突变率增加了5000倍

Read news

阅读新闻

Epitome Therapeutics was founded in 2025 by Dr. Guido Gualdoni and Dr. Jamie Hackett as a spin-off from EMBL, one of Europe’s leading life sciences research institutes. The company is developing a novel therapeutic approach based on the precise control of gene expression. While recent advances have demonstrated the potential of gene silencing, many diseases require the restoration, enhancement, or fine-tuned regulation of gene activity.

Epitome Therapeutics 由 Guido Gualdoni 博士和 Jamie Hackett 博士于 2025 年创立，是欧洲顶尖的生命科学研究机构之一——欧洲分子生物学实验室（EMBL）的衍生公司。该公司正在开发一种基于精确控制基因表达的新型治疗方法。尽管最近的进展已证实基因沉默的潜力，但许多疾病需要恢复、增强或精细调控基因活性。

This creates a need for therapeutic approaches that enable more precise control of gene expression..

这就产生了对能够更精确控制基因表达的治疗手段的需求。

“Genes don’t just need to be turned on or off—what matters is that they are expressed at exactly the right level,” said Dr. Jamie Hackett, co-founder and CSO of Epitome Therapeutics. “Many diseases arise when this balance is disrupted. The CADENCE platform enables precise control of gene expression, allowing us to restore the activity of specific genes to a therapeutically relevant level.

“基因不仅需要开启或关闭，关键在于它们必须以恰好合适的水平进行表达，”Epitome Therapeutics 的联合创始人兼首席科学官 Jamie Hackett 博士表示。“当这种平衡被打破时，许多疾病便会随之产生。CADENCE 平台能够实现对基因表达的精确控制，使我们将特定基因的活性恢复至具有治疗意义的水平。”

We are convinced that this precision medicine approach represents a fundamentally new therapeutic modality for the treatment of genetic and complex diseases.”.

我们深信，这种精准医疗方法代表了一种从根本上全新的治疗模式，可用于治疗遗传性疾病和复杂疾病。

Epitome Therapeutics’ proprietary epigenome-editing platform enables precise, long-lasting, and finely tunable activation of gene expression without altering the underlying DNA sequence. Thanks to its modular architecture, which is based on a repertoire of optimized epigenetic effectors, the platform is designed to tailor gene activation to specific biological contexts.

Epitome Therapeutics 的专有表观基因组编辑平台能够在不改变底层 DNA 序列的情况下，实现基因表达的精确、持久且可精细调控的激活。得益于其基于一系列优化表观遗传效应因子的模块化架构，该平台旨在针对特定生物学背景定制基因激活方案。

The goal is to achieve greater precision, flexibility, and safety than previous approaches. CADENCE addresses key limitations of existing gene activation technologies and is being developed for diseases caused by dysregulated gene activity, including rare diseases and metabolic disorders..

其目标是实现比以往方法更高的精确性、灵活性和安全性。CADENCE 解决了现有基因激活技术的关键局限性，正被开发用于治疗由基因活动失调引起的疾病，包括罕见病和代谢紊乱。

Epitome Therapeutics’ technology is based on research conducted at EMBL Rome, including findings published in a groundbreaking 2024 paper in *Nature Genetics*, and is supported by intellectual property exclusively licensed from EMBL.

Epitome Therapeutics 的技术基于在欧洲分子生物学实验室（EMBL）罗马分部开展的研究，包括发表在 2024 年《自然·遗传学》期刊上的一篇开创性论文中的发现，并获得了由 EMBL 独家许可的知识产权支持。

Alexander Schwartz, Partner at XISTA Science Ventures, commented: “We were very impressed by Epitome Therapeutics’ innovative approach to epigenome editing, particularly its focus on targeted upregulation. We were equally impressed by how the team plans to translate these scientific insights into therapeutically relevant development programs.

XISTA Science Ventures 合伙人 Alexander Schwartz 表示：“Epitome Therapeutics 在表观基因组编辑方面的创新方法给我们留下了深刻印象，尤其是其专注于靶向上调的策略。同样令我们印象深刻的是，该团队如何计划将这些科学见解转化为具有治疗意义的开发项目。”

We are delighted to be among the first to support the company as it takes its initial steps in development, while the field as a whole continues to gain momentum.”.

我们很高兴能在该公司迈出发展的最初步伐之际，成为首批支持者之一，而整个领域也在持续积聚势头。

“With our investment in Epitome Therapeutics, we are supporting an exceptional team that has fundamentally redefined gene regulation. We were impressed by the rare combination of scientific depth and entrepreneurial experience embodied by Guido and Jamie. We are pleased to support the team as an investor in this first major funding round,” added Gregor Unger, Managing Partner at Caesar Ventures..

“通过投资Epitome Therapeutics，我们正在支持一支从根本上重新定义基因调控的卓越团队。Guido和Jamie身上体现出的科学深度与创业经验的罕见结合令我们印象深刻。作为本轮首次重大融资的投资方，我们很高兴能够支持该团队。”凯撒创投（Caesar Ventures）管理合伙人Gregor Unger补充道。

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar.

注意：本文系通过计算机系统自动翻译而成，未经人工干预。LUMITOS 提供这些自动翻译，旨在呈现更广泛的最新新闻。由于本文采用自动翻译，可能存在词汇、句法或语法方面的错误。

The original article in German can be found .

德语原文可在以下位置找到。

here

这里

.

。

Original publication

原始出版物

Cristina Policarpi, Marzia Munafò, Stylianos Tsagkris, et al.; 'Systematic epigenome editing captures the context-dependent instructive function of chromatin modifications'; Nature Genetics, Volume 56, 2024-5-9

克里斯蒂娜·波利卡尔皮、马尔齐亚·穆纳福、斯蒂利亚诺斯·察格克里斯等；“系统性表观基因组编辑揭示了染色质修饰的背景依赖性指令功能”；《自然·遗传学》，第56卷，2024年5月9日

https://www.bionity.com/en/news/1189081/embl-spin-off-epitome-therapeutics-secures-4-million-euros-for-its-epigenome-editing-platform.html

https://www.bionity.com/en/news/1189081/embl-spin-off-epitome-therapeutics-secures-4-million-euros-for-its-epigenome-editing-platform.html

Harnessing Mutations: A Breakthrough in Fruit Fly Genetics

利用突变：果蝇遗传学的突破

A game-changing technique, TF-High-Evolutionary (TF-HighEvo), allows large-scale assessment of de-novo mutations in multicellular organisms

一项具有变革意义的技术——TF-High-Evolutionary（TF-HighEvo），使得在多细胞生物中对新生突变进行大规模评估成为可能。

Read news

阅读新闻

Most read news

阅读最多的新闻

1

1

It may not just be what’s in ultra-processed foods, but how they’re made

这可能不仅关乎超加工食品中的成分，还关乎其加工方式。

2

2

New drug could slow the development of Alzheimer’s

新药或可延缓阿尔茨海默病的发展

3

3

New antibiotics discovered to treat multi-resistant germs

发现新型抗生素以治疗多重耐药菌

4

4

Mini-Brains from Patient Cells Point to Vitamin B3 as Treatment for Rare Childhood Disease

由患者细胞培育的微型大脑指向维生素B3作为罕见儿童疾病的治疗方法

5

5

Egg consumption is associated with a lower risk of Alzheimer’s Disease

鸡蛋摄入量与阿尔茨海默病风险降低相关

Original publication

原始出版物

Cristina Policarpi, Marzia Munafò, Stylianos Tsagkris, et al.; 'Systematic epigenome editing captures the context-dependent instructive function of chromatin modifications'; Nature Genetics, Volume 56, 2024-5-9

克里斯蒂娜·波利卡尔皮、马尔齐亚·穆纳福、斯蒂利亚诺斯·察格克里斯等；“系统性表观基因组编辑揭示染色质修饰的背景依赖性指令功能”；《自然·遗传学》，第56卷，2024年5月9日

Topics

主题

epigenomes

表观基因组

gene expression

基因表达

financing

融资

pre-seed financing

种子前融资

gene regulation

基因调控

Show all

显示全部

Show less

显示较少